CN110051829A - Application of the hay bacillus fibrinolysin in treatment rhinitis drug - Google Patents
Application of the hay bacillus fibrinolysin in treatment rhinitis drug Download PDFInfo
- Publication number
- CN110051829A CN110051829A CN201910432998.5A CN201910432998A CN110051829A CN 110051829 A CN110051829 A CN 110051829A CN 201910432998 A CN201910432998 A CN 201910432998A CN 110051829 A CN110051829 A CN 110051829A
- Authority
- CN
- China
- Prior art keywords
- fibrinolysin
- hay bacillus
- nose
- bacillus
- application
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108010088842 Fibrinolysin Proteins 0.000 title claims abstract description 37
- 229940001501 fibrinolysin Drugs 0.000 title claims abstract description 37
- 241000193830 Bacillus <bacterium> Species 0.000 title claims abstract description 28
- 239000003814 drug Substances 0.000 title claims abstract description 23
- 229940079593 drug Drugs 0.000 title claims abstract description 22
- 206010039083 rhinitis Diseases 0.000 title claims abstract description 17
- 238000000855 fermentation Methods 0.000 claims abstract description 9
- 230000004151 fermentation Effects 0.000 claims abstract description 9
- 241000894006 Bacteria Species 0.000 claims abstract description 6
- 244000063299 Bacillus subtilis Species 0.000 claims abstract description 3
- 239000007788 liquid Substances 0.000 claims description 11
- 239000007921 spray Substances 0.000 claims description 5
- 239000000843 powder Substances 0.000 claims description 4
- 239000000463 material Substances 0.000 claims description 2
- 239000010902 straw Substances 0.000 claims 2
- 230000001225 therapeutic effect Effects 0.000 abstract description 3
- 210000001331 nose Anatomy 0.000 description 24
- 238000012360 testing method Methods 0.000 description 23
- 241000283977 Oryctolagus Species 0.000 description 16
- 239000012530 fluid Substances 0.000 description 13
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 12
- 241000700159 Rattus Species 0.000 description 11
- 244000025254 Cannabis sativa Species 0.000 description 10
- 201000009151 chronic rhinitis Diseases 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 229960001340 histamine Drugs 0.000 description 6
- 239000002504 physiological saline solution Substances 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 239000008280 blood Substances 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 230000000694 effects Effects 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 206010002091 Anaesthesia Diseases 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 208000036071 Rhinorrhea Diseases 0.000 description 3
- 206010039101 Rhinorrhoea Diseases 0.000 description 3
- 206010070834 Sensitisation Diseases 0.000 description 3
- 230000037005 anaesthesia Effects 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000008313 sensitization Effects 0.000 description 3
- 101710196208 Fibrinolytic enzyme Proteins 0.000 description 2
- 208000006735 Periostitis Diseases 0.000 description 2
- 206010039085 Rhinitis allergic Diseases 0.000 description 2
- 201000010105 allergic rhinitis Diseases 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 210000003746 feather Anatomy 0.000 description 2
- 239000002085 irritant Substances 0.000 description 2
- 231100000021 irritant Toxicity 0.000 description 2
- 210000004086 maxillary sinus Anatomy 0.000 description 2
- 230000007971 neurological deficit Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 210000003460 periosteum Anatomy 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000001694 spray drying Methods 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 206010011878 Deafness Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- 206010028748 Nasal obstruction Diseases 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 206010033078 Otitis media Diseases 0.000 description 1
- 208000025690 Otorhinolaryngologic disease Diseases 0.000 description 1
- 108010058846 Ovalbumin Proteins 0.000 description 1
- 241001074085 Scophthalmus aquosus Species 0.000 description 1
- 206010044302 Tracheitis Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 210000000702 aorta abdominal Anatomy 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 208000027157 chronic rhinosinusitis Diseases 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000008230 hearing development Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 210000000867 larynx Anatomy 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 238000001471 micro-filtration Methods 0.000 description 1
- 238000012148 non-surgical treatment Methods 0.000 description 1
- 208000005923 otitis media with effusion Diseases 0.000 description 1
- 229940092253 ovalbumin Drugs 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 210000001533 respiratory mucosa Anatomy 0.000 description 1
- 238000006748 scratching Methods 0.000 description 1
- 230000002393 scratching effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 208000024036 serous otitis media Diseases 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000007958 sleep Effects 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21062—Subtilisin (3.4.21.62)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Pulmonology (AREA)
- Otolaryngology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention discloses application of the hay bacillus fibrinolysin in treatment rhinitis drug, the hay bacillus fibrinolysin is made by hay bacillus Bacillus subtilis QK02 strain fermentation, the strain oneself be stored in national Type Tissue Collection, bacterium numbering CCTCCNO:M203078；Hay bacillus fibrinolysin of the invention has good therapeutic effect to rhinitis, and medication is simple to operation.
Description
Technical field
The present invention relates to treatment of rhinitis fields.It is more particularly related to which a kind of hay bacillus fibrinolysin is being treated
Application in rhinitis drug.
Background technique
Rhinitis chronic is a kind of OtorhinolaryngologicDiseases Diseases that clinic is common, main clinic symptoms be runny nose, nasal obstruction, rhiocnesmus,
Headache, secretion increase, and schneiderian membrance swelling or thicken equal obstacles, make and seriously affect to patient sleeps' mass, can also cause for a long time
The complication such as secretory otitis media, influence hearing, even result in and become deaf.Child patient also will affect facial development, hearing development
Deng.It cannot treat in time, will lead to serious consequence.Tinkling of pieces of jade et al. is paid off in " clinical ENT & HN Surgery Dept. magazine " magazine
In " epidemiologic feature of China's chronic rhinosinusitis coexisting and its parsed with disease and risk factor " research paper for delivering
In, the resident for having investigated 7, China's Mainland city carries out aspectant standardised questionnaire investigation.Research includes from 7 cities
Totally 10 636 participants, the total prevalence rate of rhinitis chronic are 8.0%, and the illness rate in 7 cities is 4.8%~9.7%.From
And speculates rhinitis chronic and about affect 1.07 hundred million population of China's Mainland.In China, rhinitis chronic is one and important public defends
Raw problem.But rhinitis chronic is up to the present still without effective therapeutic agent, still based on operation.Therefore, clinical
Lack safely and effectively non-surgical treatment.
Summary of the invention
In order to achieve the goal above, the application the invention discloses hay bacillus fibrinolysin in treatment rhinitis drug.
More preferably, application of the hay bacillus fibrinolysin in treatment rhinitis drug, the hay bacillus fibrinolysin
Be made by hay bacillus Bacillus subtilis QK02 strain fermentation, the strain oneself be stored in national type culture and protect
Hiding center, bacterium numbering CCTCCNO:M203078.
More preferably, application of the hay bacillus fibrinolysin in treatment rhinitis drug, the hay bacillus fibrinolysin
It can individually be used in the form of dry powder, or liquid sprays or liquid drops are made with pharmaceutically acceptable auxiliary material cooperation.
The present invention is include at least the following beneficial effects: hay bacillus fibrinolysin of the invention to treatment rhinitis, significant effect,
Medication is simple to operation, has no adverse reaction and complication.
Further advantage, target and feature of the invention will be partially reflected by the following instructions, and part will also be by this
The research and practice of invention and be understood by the person skilled in the art.
Specific embodiment
The present invention will be further described in detail below with reference to the embodiments, to enable those skilled in the art referring to specification
Text can be implemented accordingly.
One, the fermentation preparation of hay bacillus fibrinolysin
1, prepared by strain
Bacterial strain is placed in -80 DEG C of low temperature refrigerators and saves, strain using it is preceding with fresh slant activation for 24 hours.It is chosen from inclined-plane
Ring thallus access is taken equipped in the triangular flask of LB liquid medium, in 37 DEG C, 200r/min shaking table shaken cultivation 18h.
2, fermentor (500L) fermented and cultured
1 culture medium prescription of table
Prepare above-mentioned fermentation medium 300L, sterilising conditions are 115 DEG C, 30 minutes, after cooling room temperature, by above-mentioned 3L kind
Sub- liquid is inoculated into fermentation medium according to 1% inoculum concentration, starts fermentation for 24 hours.
3, the preparation of hay bacillus fibrinolytic enzyme powder
After fermentation, fermentation liquid is centrifuged by tube centrifuge, and it is left to obtain concentrate 25L after micro-filtration and ultrafiltration concentration
It is right.Concentrate obtains withered grass bar fibrinolysin raw material spray powder by spray drying.Spray drying condition is 140 DEG C of inlet air temperature, outlet air
Temperature is 63-68 DEG C；
Two, performance
Embodiment 1
1, test animal used: 25 new zealand rabbits, weight 4.5-4.8kg are randomly divided into 5 groups, are respectively labeled as normal
Group, model group, low dosage test group, middle dosage test group, high dose test group；
2, test method
Following methods modeling is all made of to the new zealand rabbit of model group and 3 test groups, concrete operations: rabbit bridge of the nose is hit exactly
Hair cut short, scrape light, 50mg/kg ketamine intramuscular injection anesthesia, routine disinfection, drape, 1% lidocaine art area infiltration anesthesia,
A lengthwise notch is cut along bridge of the nose median line, randomly selects side maxillary sinus antetheca, separates subcutaneous tissue and periosteum；With micro- electricity
It bores and opens the hole of a diameter about 2mm in maxillary sinus antetheca brill, Serb velveteen is seated in Dou Kou and sinus cavities, it is not necessary to completely
Block Dou Kou；It extracts 0.5ml S. aureus L-forms suspension (10CUF) and injects sinus cavities, gutstring is by periosteum, skin layer-by-layer suture；So that new west
Blue rabbit infects rhinitis chronic；
It is then daily that nose is infused respectively according to the above ratio, and continuous use 14 days；
3, drug allocation and medication
Normal group: physiological saline, nose note, 2 times a day, and each 0.5ml, continuous 14 days；
Model group: physiological saline, nose note, 2 times a day, and each 0.5ml, continuous 14 days；
Low dosage test group: with the withered grass bar fibrinolysin medical fluid of normal saline concentration 100IU, nose is infused, 2 times a day,
Each 0.5ml, continuous 14 days；
Middle dosage test group: with the withered grass bar fibrinolysin medical fluid of normal saline concentration 200IU, nose is infused, 2 times a day,
Each 0.5ml, continuous 14 days；
High dose test group: with the withered grass bar fibrinolysin medical fluid of normal saline concentration 400IU, nose is infused, 2 times a day,
Each 0.5ml, continuous 14 days；
4, interpretation of result
The blood of each group new zealand rabbit is checked, specific data target record is as follows:
Influence of the 1 withered grass bar fibrinolysin medical fluid of table to new zealand rabbit tracheitis data
As seen from the results in Table 1, hay bacillus fibrinolysin of the invention has obvious therapeutic effect to rhinitis；Via of the invention
The indices of the new zealand rabbit of hay bacillus fibrinolytic enzyme treatment are all tried close to the new zealand rabbit normally organized, especially high dose
The recovery effects for testing the new zealand rabbit of group are best, and indices are close to normal group；
Embodiment 2
1, test animal used: 25 rats, weight 28-36g are randomly divided into 5 groups, are respectively labeled as normal group, model
Group, low dosage test group, middle dosage test group, high dose test group；
2, test method
Following methods modeling is all made of to the rat of model group and 3 test groups；Concrete operations: raw with 2% ovalbumin
It manages brine spray and collunarium stimulation (both sides nose carries out simultaneously, every side nose every time 5 μ L) is carried out to rat, continue 10 days, it is complete
At sensitization modeling；
Wherein, sneeze number and rhiocnesmus degree are observed and recorded daily；Specific targets are as follows:
Rhiocnesmus is slight: dabbing nose several times, remembers 1 point；
Rhiocnesmus severe: scratching nose, face are more than, rub everywhere, remember 2 points；
Sneeze is slight: 1-3, remembering 1 point；
Sneeze moderate: 4-10, remember 2 points；
Sneeze severe: 11 or more, remember 3 points；
It has a running nose: flowing to anterior naris, remember 1 point；More than anterior naris, 2 points are remembered；Runny nose is had one's face covered with, and remembers 3 points；
Each symptom statistical stacking, gross score is up to 5 points, i.e. sensitization modeling success；
3, drug allocation and medication
Normal group: physiological saline, nose note, 2 times a day, and each 0.5ml, continuous 14 days；
Model group: physiological saline, nose note, 2 times a day, and each 0.5ml, continuous 14 days；
Low dosage test group: with the withered grass bar fibrinolysin medical fluid of normal saline concentration 500IU, dosage 35mg/kg
Weight；
Middle dosage test group: with the withered grass bar fibrinolysin medical fluid of normal saline concentration 500IU, dosage 35mg/kg
Weight；
High dose test group: with the withered grass bar fibrinolysin medical fluid of normal saline concentration 500IU, dosage 35mg/kg
Weight；
4, pharmacodynamic test observation index and method
(1) neurological deficit score standard
Sneeze number and rhiocnesmus degree are observed and recorded daily；
The comparison of every group of rat behavior scoring average mark before and after 2 nose injecting medical liquid of table
Note: * * P < 0.01, * P < 0.05 compared with model group
By the result of above-mentioned table 2 it is found that after using hay bacillus fibrinolysin medical fluid nose of the present invention note treatment, the spray of rat
Sneeze number and runny nose situation is improved well, and the neurological deficit score standard of rat substantially reduces, and is all restored close to just substantially
Often, the especially high dose test group of high dose is restored substantially to close to normal group, and the model group of sensitization is not adopted
Treatment is infused with hay bacillus fibrinolysin medical fluid nose of the invention, Rhinitis Symptoms are still apparent.
(2) the nose injecting medical liquid of rat is measured before and after nose injecting medical liquid 14 days, anesthesia execution is carried out to rat, and take it
Abdominal aorta blood 2ml, -20 DEG C save backup, and extract histamine, with fluorescence spectrophotometry histamine content, group in blood
The content of amine；
After 3 nose injecting medical liquid of table in rat blood histamine content balance
Note: * * P < 0.01, * P < 0.05 compared with model group
By the result of above-mentioned table 3 it is found that after using hay bacillus fibrinolysin medical fluid nose of the present invention note treatment, rat serum night
In histamine content be all greatly lowered, substantially close to the blood histamine value of normal rats, and histamine is as anaphylaxis
One of the important reference indicator of rhinitis curative effect of medication, is greatly lowered, and surface hay bacillus fibrinolysin of the invention can have
Effect improves allergic rhinitis symptoms.
Embodiment 3, toxicity test
3.1 intact skin irritant tests
10 new zealand rabbits, weight 4.5-4.8g are raised according to normal condition before the test, by new zealand rabbit back
Shaving forms the medication area lost hair or feathers and contrast district of two pieces of 2cm*2cm, wherein the withered grass of medication area coating concentration 400IU
The physiological saline of 1.0 μ L of bacillus fibrinolysin medical fluid, contrast district coating equivalent are adhered to 14 days 1 time a day；It is strong according to skin irritatin
Standards of grading are spent, it is nonirritant to the intact skin of new zealand rabbit that hay bacillus fibrinolysin of the invention can be evaluated；
3.2 damaged skin irritant tests
10 new zealand rabbits, weight 4.5-4.8g are raised according to normal condition before the test, by new zealand rabbit back
Shaving forms the medication area lost hair or feathers and contrast district of two pieces of 2cm*2cm, draws consistent cut in medication area, contrast district respectively
Mouthful, avoid bleeding, wherein medication area coats the 1.0 μ L of hay bacillus fibrinolysin medical fluid of concentration 400IU, and contrast district coats equivalent
Physiological saline adhere to 14 days 1 time a day；According to skin irritatin intensity ratings standard, withered grass bar of the invention can be evaluated
Bacterium fibrinolysin is nonirritant to the damaged skin of new zealand rabbit；
3.3 acute toxicity test
10 new zealand rabbits, the hay bacillus fibrinolysin medical fluid of weight 4.5-4.8g, nose implantation concentration 400IU, daily 3
Secondary, each 3ml observes and records the death condition, changes of weight and other symptoms of new zealand rabbit daily；
It 14th day, puts to death, each organ is taken to carry out pathologic finding；
As a result: at 14 days, whole new zealand rabbit survivals, no death, and each organ pathology is found through histopathological examination
It checks normally, and the respiratory mucosas such as nose, larynx, trachea-bronchial epithelial cell have no damaging variation；
And during this period, significant change does not occur for the weight of rabbit, also without any discomfort symptom；
The above results all show that hay bacillus fibrinolysin not only has rhinitis (including rhinitis chronic and allergic rhinitis)
Good therapeutic effect, and in animal experiment, toxic reaction is also not present.
Although the embodiments of the present invention have been disclosed as above, but its is not only in the description and the implementation listed
With, therefore without departing from the general concept defined in the claims and the equivalent scope, the present invention is not limited to specific thin
Section and embodiment shown and described herein.
Claims (3)
1. application of the hay bacillus fibrinolysin in treatment rhinitis drug.
2. application of the hay bacillus fibrinolysin as described in claim 1 in treatment rhinitis drug, which is characterized in that described withered
Straw bacterium fibrinolysin is made by hay bacillus Bacillus subtilis QK02 strain fermentation, the strain oneself be stored in national allusion quotation
Type culture collection, bacterium numbering CCTCCNO:M203078.
3. application of the hay bacillus fibrinolysin as described in claim 1 in treatment rhinitis drug, which is characterized in that described withered
Straw bacterium fibrinolysin can be used individually in the form of dry powder, or liquid sprays are made with pharmaceutically acceptable auxiliary material cooperation
Or liquid drops.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910432998.5A CN110051829A (en) | 2019-05-23 | 2019-05-23 | Application of the hay bacillus fibrinolysin in treatment rhinitis drug |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910432998.5A CN110051829A (en) | 2019-05-23 | 2019-05-23 | Application of the hay bacillus fibrinolysin in treatment rhinitis drug |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110051829A true CN110051829A (en) | 2019-07-26 |
Family
ID=67324185
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910432998.5A Pending CN110051829A (en) | 2019-05-23 | 2019-05-23 | Application of the hay bacillus fibrinolysin in treatment rhinitis drug |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110051829A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111840384A (en) * | 2020-08-01 | 2020-10-30 | 武汉真福医药股份有限公司 | Anti-senile plaque composition and preparation method thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110129454A1 (en) * | 2009-11-23 | 2011-06-02 | Prothera, Inc. | Compositions and methods comprising serratia peptidase for inhibition and treatment of biofilms related to certain conditions |
| CN105535950A (en) * | 2016-02-02 | 2016-05-04 | 武汉真福医药股份有限公司 | Method for preparing plasmin composition and application of plasmin composition |
| CN106222151A (en) * | 2016-08-31 | 2016-12-14 | 武汉真福医药股份有限公司 | A kind of recombination bacillus subtilis fibrinolysin and the preparation method of enteric coated capsule thereof |
-
2019
- 2019-05-23 CN CN201910432998.5A patent/CN110051829A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110129454A1 (en) * | 2009-11-23 | 2011-06-02 | Prothera, Inc. | Compositions and methods comprising serratia peptidase for inhibition and treatment of biofilms related to certain conditions |
| CN105535950A (en) * | 2016-02-02 | 2016-05-04 | 武汉真福医药股份有限公司 | Method for preparing plasmin composition and application of plasmin composition |
| CN106222151A (en) * | 2016-08-31 | 2016-12-14 | 武汉真福医药股份有限公司 | A kind of recombination bacillus subtilis fibrinolysin and the preparation method of enteric coated capsule thereof |
Non-Patent Citations (7)
| Title |
|---|
| TETSUJI TAKABAYASHI等: "Nattokinase, profibrinolytic enzyme, effectively shrinks the nasal polyp tissue and decreases viscosity of mucus", 《ALLERGOLOGY INTERNATIONAL》, vol. 66, no. 4, 4 April 2017 (2017-04-04), pages 1 - 2 * |
| 张立等: "枯草杆菌溶栓酶QK-2发酵工艺的优化及其肠溶胶囊的研制", 《2012年湖北生物产业发展高端论坛暨湖北省生物工程学会2012年度学术交流会论文汇编》 * |
| 张立等: "枯草杆菌溶栓酶QK-2发酵工艺的优化及其肠溶胶囊的研制", 《2012年湖北生物产业发展高端论坛暨湖北省生物工程学会2012年度学术交流会论文汇编》, 25 September 2012 (2012-09-25) * |
| 徐寒梅等: "治疗酶的研究进展", 《生物工程学报》 * |
| 徐寒梅等: "治疗酶的研究进展", 《生物工程学报》, vol. 25, no. 12, 25 December 2009 (2009-12-25), pages 1852 - 1862 * |
| 章玲等, 天津科学技术出版社 * |
| 章玲等: "新编临床五官科疾病诊疗学", 天津科学技术出版社, pages: 279 - 281 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111840384A (en) * | 2020-08-01 | 2020-10-30 | 武汉真福医药股份有限公司 | Anti-senile plaque composition and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101648018A (en) | Medicinal composition for treating ophthalmic inflammation and application thereof | |
| CN105934155A (en) | Methods of using adipose tissue-derived cells in the modulation of pain and/or fibrosis | |
| Nungester | Mechanisms of man's resistance to infectious diseases | |
| CN110038122A (en) | Application of the hay bacillus fibrinolysin in treatment bronchitis drug | |
| CN106215171A (en) | A kind of mesenchymal stem cell injection and its preparation method and application | |
| CN114425033B (en) | Eye gel containing mesenchymal stem cell exosomes and preparation method thereof | |
| Pan et al. | Combined transplantation with human mesenchymal stem cells improves retinal rescue effect of human fetal RPE cells in retinal degeneration mouse model | |
| TWI666324B (en) | Cicada flower active substance and its use for reducing intraocular pressure | |
| CN110051829A (en) | Application of the hay bacillus fibrinolysin in treatment rhinitis drug | |
| CN105012235B (en) | A kind of ophthalmically acceptable antimycotic nano micellar solution containing terbinafine HCl | |
| CN101648019A (en) | Medicinal composition for treating ophthalmic inflammation and application thereof | |
| CN110101851A (en) | Hay bacillus fibrinolysin is treating the application in cerebral ischemia re-pouring injured drug | |
| CN109793740A (en) | Application of the pazopanib hydrochloride in preparation treatment pulmonary fibrosis disease drug | |
| CN110960485B (en) | Medicine for treating keratitis and preparation method thereof | |
| TW202041222A (en) | Medical uses of mesenchymal stem cells in prevention and treatment of emotional disorders | |
| CN102512664A (en) | Nerve growth factor composition | |
| JP6502350B2 (en) | Non-anesthetic protective gas combined with liquid anesthetics for organ protection | |
| CN104302657B (en) | Methods of using immunomodulating peptide for treating or preventing inflammatory related diseases | |
| CN103948581B (en) | Levocarnitine combines L-arginine and is preparing the application in treating diabetic retinopathy neurotrosis medicine | |
| CN101879161A (en) | Application of N-[4-(monohydro-pyrazol-4-) phenyl]-2,3-dihydro-1,4-benzdioxan-2-amide derivative in preparing drug for treating glaucoma | |
| Bo et al. | Therapeutic effect of small extracellular vesicles derived from mesenchymal stem cells on retinal light injury and its mechanism | |
| CN109745548A (en) | A kind of application of pertussis toxin in treatment cerebral infarction | |
| CN105749297B (en) | The method for building up of the animal model of charrin disease pneumonia | |
| CN100360185C (en) | Preparation method of medicine for treating pelada | |
| CN107823337A (en) | A kind of allergic rhinitis oil formula and its preparation technology |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20190726 |
|
| RJ01 | Rejection of invention patent application after publication |